80-10 Northern Blvd, Jackson Heights, NY 11372
Coverage depends on your exact plan, clinician, location and service. Check participation and expected charges with the clinic and your insurer before booking.
Self-pay visits can also be reviewed when insurance is not workable or when a faster evaluation path makes more sense. The visit, labs, medication acquisition, and administration steps are not always one bundled number, so the care team walks through the path before the schedule is locked.
Confirm that the selected location can perform or coordinate the required HIV tests, receive the prescribed medication and provide professional gluteal injections on the target dates. Ask whether your evaluation and first injection are separate appointments and whether results from another laboratory can be accepted. Apretude is not a take-home self-injection product. Bring previous PrEP dates and a complete medication list, and identify the prescriber responsible for results, delays and alternative coverage. If another administration site is needed, use a current official locator and confirm the site's own service and payer requirements. A location listing alone does not establish medication stock, an open appointment or coverage. Book follow-up around the actual calendar before arranging repeated travel.
Apretude is long-acting cabotegravir used to reduce the chance of acquiring HIV-1 through sex. It is for people who do not have HIV. A healthcare professional gives the injection into a gluteal muscle. It can reduce the burden of taking a daily pill, but it replaces that routine with scheduled injections and HIV testing. It does not prevent other sexually transmitted infections or pregnancy. Choosing it means planning both the first visits and what to do if travel, insurance or illness disrupts a later appointment.
Cabotegravir blocks HIV integrase, an enzyme the virus needs to establish infection. Drug remains in the body for a long time after an injection. As levels fall, the remaining medicine may be insufficient protection and could allow resistant HIV to develop if infection occurs. This is why HIV testing and a plan for stopping or changing PrEP are part of treatment.
The US indication includes adults and adolescents who weigh at least 35 kg and are at risk of sexually acquired HIV. A clinician must confirm HIV-negative status and assess recent exposure and symptoms of acute HIV. Fever, rash, sore throat or swollen glands after a possible exposure need assessment even if a rapid test is negative. Apretude is not an adequate HIV treatment regimen. Relevant allergies, liver disease, pregnancy or breastfeeding, mental-health history and interacting medicines affect the discussion.
Discuss exposure, previous PrEP, adherence, injection preferences and ability to return. If possible HIV exposure occurred within the last 72 hours, seek urgent PEP assessment instead of waiting for a routine PrEP visit.
The plan includes an HIV antigen/antibody test and HIV RNA testing before injections. A negative antigen/antibody result requires RNA confirmation, even when the RNA result returns after an injection. Unclear or discordant results require clinical review before proceeding.
An oral cabotegravir lead-in may be offered to assess tolerability; it is optional. The first two injections are one month apart, followed by an injection every two months. Your team sets the target dates and explains the permitted appointment window.
Agree on STI screening, symptom contact, reminders and an alternative PrEP plan if injections stop. Bring up anticipated travel before a dose becomes overdue.
Bring your medication and supplement list, recent HIV results, dates of prior PrEP doses and information about insurance. Tell the clinician about medicines for seizures, TB or other infections: some reduce cabotegravir levels. Ask whether testing and injection happen at the same visit, who follows pending RNA results and when the next appointment is booked. These arrangements must be confirmed for your chosen location.
Injection-site pain and tenderness are common. Discuss symptom relief with your clinician rather than choosing medicines from a forum. Call 911 for trouble breathing, facial swelling, fainting or a severe allergic reaction. A severe rash needs immediate medical assessment. Report jaundice, dark urine or persistent severe symptoms promptly. Depression and suicidal thoughts have been reported with cabotegravir; contact a clinician promptly for a major mood change and call 911 or go to the emergency department for immediate danger. Do not self-inject Apretude or use leftover tablets to design a bridge.
Continuing visits assess HIV status, exposure, adverse effects and STI prevention. Contact the prescribing team as soon as an appointment may be missed. Planned and unplanned delays have different label pathways; the team may prescribe oral coverage or change the restart schedule. After stopping, CDC recommends continuing HIV antigen/antibody and RNA testing every three months for 12 months. Another effective prevention method may be needed before protection wanes.
An evaluation, authorization and an injection appointment are separate steps. Ask about the medication benefit, administration fee, laboratory charges, supply route and the site that will actually administer it. Confirm these details before visiting and keep an agreed prevention plan while access is arranged.
Nao Medical Jackson Heights: 80-10 Northern Blvd, Jackson Heights, NY 11372. Call +1-917-310-3371 to confirm the specific service, clinician and appointment before travelling.
Contact the clinic to confirm this service, the clinician and appointment preparation. General clinic hours may differ from service appointment times.
Nao Medical can assess your HIV-prevention needs and arrange APRETUDE care when appropriate. The plan includes HIV testing and scheduled injection visits. Confirm the first appointment and medication arrangements, and contact the PrEP clinician before travel or a missed injection. A possible HIV exposure within 72 hours needs urgent PEP assessment.
Apretude is long-acting cabotegravir used to reduce the chance of acquiring HIV-1 through sex. It is for people who do not have HIV. A healthcare professional gives the injection into a gluteal muscle. It can reduce the burden of taking a daily pill, but it replaces that routine with scheduled injections and HIV testing. It does not prevent other sexually transmitted infections or pregnancy. Choosing it means planning both the first visits and what to do if travel, insurance or illness disrupts a later appointment.
The US indication includes adults and adolescents who weigh at least 35 kg and are at risk of sexually acquired HIV. A clinician must confirm HIV-negative status and assess recent exposure and symptoms of acute HIV. Fever, rash, sore throat or swollen glands after a possible exposure need assessment even if a rapid test is negative. Apretude is not an adequate HIV treatment regimen. Relevant allergies, liver disease, pregnancy or breastfeeding, mental-health history and interacting medicines affect the discussion.
Discuss exposure, previous PrEP, adherence, injection preferences and ability to return. If possible HIV exposure occurred within the last 72 hours, seek urgent PEP assessment instead of waiting for a routine PrEP visit.
The plan includes an HIV antigen/antibody test and HIV RNA testing before injections. A negative antigen/antibody result requires RNA confirmation, even when the RNA result returns after an injection. Unclear or discordant results require clinical review before proceeding.
An oral cabotegravir lead-in may be offered to assess tolerability; it is optional. The first two injections are one month apart, followed by an injection every two months. Your team sets the target dates and explains the permitted appointment window.
Agree on STI screening, symptom contact, reminders and an alternative PrEP plan if injections stop. Bring up anticipated travel before a dose becomes overdue.
Insurance and self-pay need separate confirmation. Ask the Apretude service and your exact plan about evaluation, HIV/STI testing, medicine, injection administration and follow-up, including network and authorization requirements. If you prefer self-pay, request the full written estimate and ask which clinic, pharmacy and laboratory bills are separate. No payment choice guarantees an injection or a suitable prescription.
Continuing visits assess HIV status, exposure, adverse effects and STI prevention. Contact the prescribing team as soon as an appointment may be missed. Planned and unplanned delays have different label pathways; the team may prescribe oral coverage or change the restart schedule. After stopping, CDC recommends continuing HIV antigen/antibody and RNA testing every three months for 12 months. Another effective prevention method may be needed before protection wanes.
Discuss exposure, previous PrEP, adherence, injection preferences and ability to return. If possible HIV exposure occurred within the last 72 hours, seek urgent PEP assessment instead of waiting for a routine PrEP visit.
The plan includes an HIV antigen/antibody test and HIV RNA testing before injections. A negative antigen/antibody result requires RNA confirmation, even when the RNA result returns after an injection. Unclear or discordant results require clinical review before proceeding.
An oral cabotegravir lead-in may be offered to assess tolerability; it is optional. The first two injections are one month apart, followed by an injection every two months. Your team sets the target dates and explains the permitted appointment window.
Agree on STI screening, symptom contact, reminders and an alternative PrEP plan if injections stop. Bring up anticipated travel before a dose becomes overdue.
No. The oral lead-in is optional. Your clinician can discuss tolerability assessment and direct-to-injection initiation. Continue your current prevention plan until the clinician gives a specific transition plan.
Contact your prescribing team promptly with the last injection date and the planned next date. Do not assume residual medicine guarantees protection. The appropriate oral bridge or restart depends on the actual delay and HIV assessment.
Discuss injection pain, prior reactions and your work demands before the visit. Some people have soreness that affects sitting or activity. There is no universal amount of time off work; arrange a practical plan and report severe or worsening symptoms.
Bronx
932 E 174th St, Bronx, NY 10460
A Bronx access point for long-acting PrEP scheduling, HIV testing coordination, and reliable follow-up for patients in West Farms, Crotona Park East, and nearby Bronx neighborhoods.
View APRETUDE location details Get directions
Queens
37-15 23rd Ave, Astoria, NY 11105
A Queens access point for long-acting PrEP scheduling, HIV testing coordination, and reliable follow-up for patients in Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods.
View APRETUDE location details Get directions
Bronx
2063A Bartow Ave, Bronx, NY 10475
A Bronx access point for long-acting PrEP scheduling, HIV testing coordination, and reliable follow-up for patients in Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods.
View APRETUDE location details Get directions
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
A Brooklyn access point for long-acting PrEP scheduling, HIV testing coordination, and reliable follow-up for patients in Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods.
View APRETUDE location details Get directions
Long Island
232 W Old Country Rd, Hicksville, NY 11801
A Long Island access point for long-acting PrEP scheduling, HIV testing coordination, and reliable follow-up for patients in Hicksville, Plainview, Bethpage, and nearby Nassau County communities.
View APRETUDE location details Get directions
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
A Queens access point for long-acting PrEP scheduling, HIV testing coordination, and reliable follow-up for patients in Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods.
View APRETUDE location details Get directions
Queens
30-07 36th Ave, Astoria, NY 11106
A Queens access point for long-acting PrEP scheduling, HIV testing coordination, and reliable follow-up for patients in Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods.
View APRETUDE location details Get directions
Long Island
135 Mineola Blvd, Mineola, NY 11501
A Long Island access point for long-acting PrEP scheduling, HIV testing coordination, and reliable follow-up for patients in Mineola, Garden City, Westbury, and nearby Nassau County communities.
View APRETUDE location details Get directions
Manhattan
259 1st Ave, New York, NY 10003
A Manhattan access point for long-acting PrEP scheduling, HIV testing coordination, and reliable follow-up for patients in StuyTown, East Village, Gramercy, and nearby Manhattan neighborhoods.
View APRETUDE location details Get directions
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
A Brooklyn access point for long-acting PrEP scheduling, HIV testing coordination, and reliable follow-up for patients in Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods.
View APRETUDE location details Get directionsUse the scheduling guidance when the main question is how to keep the injection cadence realistic across work, travel, and follow-up testing.
Use the workflow guide for the sequence from candidacy and HIV-negative confirmation through initiation and long-term maintenance.
Use the insurance guidance when the main blocker is coverage, prior authorization, or whether self-pay makes more sense.
Use the locations guidance when geography or administration setting is the main issue instead of medication choice.
Use the HIV testing overview when the immediate need is testing, results discussion, or follow-up rather than long-acting PrEP access.
Use the broader STD testing overview when patients need a wider sexual-health workup, symptoms review, or related testing beyond HIV prevention.
Arrange an evaluation to discuss suitable care, preparation and follow-up with a clinician.
Book PrEP visit